X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
D-PLEX (doxycycline) is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent surgical site infections (SSIs).
Lead Product(s): Doxycycline
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
The Company intends to use the net proceeds for its ongoing SHIELD II phase 3 clinical trial evaluating D-PLEX100 (extended release doxycycline hyclate formulation) for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JMP Securities
Deal Size: $16.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 04, 2024
Details:
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $7.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 31, 2023
Details:
PolyPid intends to use the net proceeds from the Public Offering to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $6.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 29, 2023
Details:
PolyPid intends to use the net proceeds from the private placement to fund the ongoing clinical activities and development of D-PLEX100 (doxycycline hyclate). D-PLEX100 is in Phase 3 clinical trials for the prevention of abdominal colorectal surgical site infections.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Newbridge Securities Corporation
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 29, 2023
Details:
D-PLEX100 (doxycycline hyclate) is polyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs.
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Details:
D-PLEX100 (Doxycycline hyclate), is designed to provide local prolonged release and controlled activity of the broad-spectrum antibiotic doxycycline directly at the surgical site to prevent surgical site infections (SSIs).
Lead Product(s): Doxycycline Hyclate
Therapeutic Area: Infections and Infectious Diseases Product Name: D-PLEX100
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
